Lyle Stein Pfizer Inc PFE-N WATCH Jul 18, 2025

Hangover from its Covid highs. Working on an obesity pill, but pulled back on it. Opportunities in the pipeline. Owned in his income growth portfolio for the yield. Despite the chart, likes it here. Fairly cheap, hopefully hitting a bottom (knock wood).

It can bottom here. He believes in their Seagen acquisition.

Once upon a time, he really liked it. Beaten up for inability to bring forward a weight-loss drug; that may or may not be a realistic critique of this stock long term. Analyst community is really...just...waiting. He sold last year, not ready to come back in. Solid company, an improved oncology pipeline might be a reason to get back in.

Pays a 7% dividend. Something good must be coming out of their Seagen acquisition. The pipeline looks promising.

He owned it but sold. Free cash flow is not abundant and it has a lot of debt. It will take time to turn around but pays a good dividend.

She likes the space but people are not investing in it. It has a low valuation and is tempting but she prefers elsewhere. It is a global leader in a crowded field. She sees 5% growth so there is some upside.

It needs a catalyst, like a new cancer formulation. Otherwise, you're just collecting that 6.75% dividend.

The problem with pharma is that their drugs all face a patent cliff. Over the last 25 years, pharma companies have tried to sustain themselves through consolidation (mergers, buying small companies). Caution: the dividend may look attractive, but that could be the result of the falling share price.

Laggard. Doesn't see anything in the healthcare sector that points to a turnaround in the near term. Target on the sector's back on margins. Stock's bounced over the last few weeks, use that to move on.